Viridian Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Viridian Therapeutics, Inc. carries a market capitalization of 2.60B, placing it among publicly traded companies globally. Its enterprise value stands at 1.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.60B |
| Enterprise Value | 1.44B |
Share Statistics
Viridian Therapeutics, Inc. currently has 113.24M shares outstanding.
| Shares Outstanding | 113.24M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 24.94, and the price-to-book ratio stands at 3.69.
| PE Ratio | N/A |
| PS Ratio | 24.94 |
| PB Ratio | 3.69 |
| P/TBV Ratio | 3.75 |
| P/FCF Ratio | -5.35 |
| P/OCF Ratio | -5.32 |
Enterprise Valuation
| EV / Sales | 20.24 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Viridian Therapeutics, Inc. maintains a current ratio of 16.95, meaning it holds 16.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.68, indicating elevated leverage, while an interest coverage ratio of -25.93 demonstrates limited ability to service its debt obligations.
| Current Ratio | 16.95 |
| Quick Ratio | 16.56 |
| Debt / Equity | 36.68 |
| Debt / EBITDA | -0.60 |
| Interest Coverage | -25.93 |
Financial Efficiency
| Return on Equity (ROE) | -86.93 |
| Return on Assets (ROA) | -46.08 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Viridian Therapeutics, Inc.'s stock has gained approximately 22.96137% over the past 52 weeks. The 50-day moving average sits at 20.97, while the 200-day moving average is 23.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | 22.96137% |
| 50-Day Moving Average | 20.97 |
| 200-Day Moving Average | 23.81 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Viridian Therapeutics, Inc. generated 71.13M in revenue and converted that into -386.97M in net income, yielding earnings per share of -4.01. EBITDA reached -404.73M, while operating income came in at -405.20M.
| Revenue | 71.13M |
| Gross Profit | N/A |
| Operating Income | -405.20M |
| Pretax Income | -386.97M |
| Net Income | -386.97M |
| EBITDA | -404.73M |
| EBIT | -405.20M |
| Earnings Per Share (EPS) | -4.01 |
Balance Sheet
Viridian Therapeutics, Inc. holds 981.53M in cash and equivalents against 242.88M in total debt, resulting in a net debt position of 77.17M. Total book value stands at 564.07M, with working capital of 1.02B providing operational flexibility.
| Cash & Cash Equivalents | 981.53M |
| Total Debt | 242.88M |
| Net Debt | 77.17M |
| Equity (Book Value) | 564.07M |
| Book Value Per Share | 4.98 |
| Working Capital | 1.02B |
Cash Flow
Viridian Therapeutics, Inc. produced -333.34M in operating cash flow over the past twelve months. After subtracting -1.70M in capital expenditures, free cash flow totaled -335.04M - equivalent to -3.47 per share.
| Operating Cash Flow | -333.34M |
| Capital Expenditures | -1.70M |
| Free Cash Flow | -335.04M |
| FCF Per Share | -3.47 |
Margins
Viridian Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -569.68 and net profit margin of -544.06 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -569.68 |
| Pretax Margin | -544.06 |
| Profit Margin | -544.06 |
| EBITDA Margin | -569.03 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -35.97 |
| FCF Yield | -18.70 |
Stock Splits
Viridian Therapeutics, Inc.'s most recent stock split took place on November 13, 2020 with a 15:1 split ratio.
| Last Split Date | 11/13/2020 |
| Split Ratio | 15:1 |
Scores
Viridian Therapeutics, Inc. posts an Altman Z-Score of 0.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.80 |